Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0I4BC
|
||||
Former ID |
DNC008235
|
||||
Drug Name |
1-(2-(naphthalen-2-yl)ethyl)pyrrolidine
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C16H19N
|
||||
Canonical SMILES |
C1CCN(C1)CCC2=CC3=CC=CC=C3C=C2
|
||||
InChI |
1S/C16H19N/c1-2-6-16-13-14(7-8-15(16)5-1)9-12-17-10-3-4-11-17/h1-2,5-8,13H,3-4,9-12H2
|
||||
InChIKey |
BUFGWZZSSJWXIJ-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Histamine H3 receptor | Target Info | Inhibitor | [1] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
Reactome | Histamine receptors | ||||
G alpha (i) signalling events | |||||
WikiPathways | Monoamine Transport | ||||
GPCRs, Class A Rhodopsin-like | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. Epub 2007 Oct 24.In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.